CLOs on the Move

LGM Pharma

www.lgmpharma.com

 
LGM Pharma is an innovation-driven API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. We specialize in streamlining the API supply chain management throughout all development and commercial stages while providing complete technical capabilities and expert regulatory support.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Syneos Health

"Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers` delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. "

Cedarburg Hauser Pharmaceuticals

Cedarburg Hauser Pharmaceuticals is a Grafton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Connecticut Orthopaedics

Connecticut Orthopaedics is a premier team of orthopaedic doctors, surgeons and health care professionals that keep you moving forward with life. Learn more

Lyra Therapeutics

We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.